JP2021531346A5 - - Google Patents
Info
- Publication number
- JP2021531346A5 JP2021531346A5 JP2021526403A JP2021526403A JP2021531346A5 JP 2021531346 A5 JP2021531346 A5 JP 2021531346A5 JP 2021526403 A JP2021526403 A JP 2021526403A JP 2021526403 A JP2021526403 A JP 2021526403A JP 2021531346 A5 JP2021531346 A5 JP 2021531346A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701467P | 2018-07-20 | 2018-07-20 | |
| US62/701,467 | 2018-07-20 | ||
| PCT/US2019/042597 WO2020023310A1 (en) | 2018-07-20 | 2019-07-19 | Compositions of fcrn antibodies and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531346A JP2021531346A (ja) | 2021-11-18 |
| JP2021531346A5 true JP2021531346A5 (enExample) | 2022-06-20 |
| JP7457704B2 JP7457704B2 (ja) | 2024-03-28 |
Family
ID=69180697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526403A Active JP7457704B2 (ja) | 2018-07-20 | 2019-07-19 | Ｆｃｒｎ抗体の組成物およびその使用の方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210299255A1 (enExample) |
| EP (1) | EP3826641A4 (enExample) |
| JP (1) | JP7457704B2 (enExample) |
| KR (1) | KR20210105872A (enExample) |
| CN (1) | CN113301903A (enExample) |
| AU (1) | AU2019312139B2 (enExample) |
| BR (1) | BR112021001017A2 (enExample) |
| CA (1) | CA3106669A1 (enExample) |
| CR (1) | CR20210088A (enExample) |
| EA (1) | EA202190335A1 (enExample) |
| IL (1) | IL280280B2 (enExample) |
| JO (2) | JOP20210015A1 (enExample) |
| MX (1) | MX2021000790A (enExample) |
| PH (1) | PH12021550096A1 (enExample) |
| SG (1) | SG11202100420UA (enExample) |
| WO (1) | WO2020023310A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64768B1 (sr) | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals Inc | Fcrn antitela i načini njihove upotrebe |
| KR102904658B1 (ko) | 2017-12-13 | 2025-12-29 | 모멘타 파머슈티컬스 인코포레이티드 | FcRn 항체 및 이의 사용 방법 |
| CN113518783A (zh) | 2018-07-20 | 2021-10-19 | 动量制药公司 | FcRn抗体组合物 |
| IL302516A (en) * | 2020-11-06 | 2023-07-01 | Janssen Biotech Inc | FCRN antibodies and methods of using them |
| US20240182598A1 (en) * | 2021-04-12 | 2024-06-06 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating pediatric myasthenia gravis |
| WO2024163894A1 (en) | 2023-02-04 | 2024-08-08 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating hemolytic disease of the fetus and newborn |
| CN116539488B (zh) * | 2023-05-11 | 2023-11-24 | 中国食品药品检定研究院 | 一种体外评价生物制品稳定性的方法、系统及设备 |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025163617A1 (en) | 2024-02-04 | 2025-08-07 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
| WO2025186787A1 (en) | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
| WO2025259928A1 (en) * | 2024-06-13 | 2025-12-18 | Obi Pharma, Inc. | Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof |
| WO2026083290A1 (en) | 2024-10-16 | 2026-04-23 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating sjögren's disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03504499A (ja) * | 1988-05-27 | 1991-10-03 | セントカー・インコーポレーテツド | 抗体試薬のための配合物 |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| CN101721362B (zh) * | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| ES2569409T3 (es) * | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| US20110027267A1 (en) * | 2007-11-09 | 2011-02-03 | Anaphore, Inc. | Fusion Proteins of Mannose Binding Lectins for Treatment of Disease |
| WO2009124294A2 (en) | 2008-04-05 | 2009-10-08 | Lpath, Inc. | Pharmaceutical compositions for binding sphingosine-1-phosphate |
| JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US9844594B2 (en) * | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
| RS64768B1 (sr) | 2015-01-30 | 2023-11-30 | Momenta Pharmaceuticals Inc | Fcrn antitela i načini njihove upotrebe |
| WO2017015622A2 (en) * | 2015-07-22 | 2017-01-26 | Scholar Rock, Inc | Gdf11 binding proteins and uses thereof |
| SMT202400004T1 (it) * | 2016-07-29 | 2024-03-13 | Momenta Pharmaceuticals Inc | Anticorpi fcrn e loro metodi di utilizzo |
-
2019
- 2019-07-19 WO PCT/US2019/042597 patent/WO2020023310A1/en not_active Ceased
- 2019-07-19 MX MX2021000790A patent/MX2021000790A/es unknown
- 2019-07-19 IL IL280280A patent/IL280280B2/en unknown
- 2019-07-19 BR BR112021001017-3A patent/BR112021001017A2/pt unknown
- 2019-07-19 KR KR1020217003706A patent/KR20210105872A/ko not_active Abandoned
- 2019-07-19 JO JOP/2021/0015A patent/JOP20210015A1/ar unknown
- 2019-07-19 CN CN201980061788.8A patent/CN113301903A/zh active Pending
- 2019-07-19 PH PH1/2021/550096A patent/PH12021550096A1/en unknown
- 2019-07-19 EP EP19840439.4A patent/EP3826641A4/en not_active Withdrawn
- 2019-07-19 CA CA3106669A patent/CA3106669A1/en active Pending
- 2019-07-19 CR CR20210088A patent/CR20210088A/es unknown
- 2019-07-19 JP JP2021526403A patent/JP7457704B2/ja active Active
- 2019-07-19 JO JOP/2021/0014A patent/JOP20210014A1/ar unknown
- 2019-07-19 US US17/260,318 patent/US20210299255A1/en active Pending
- 2019-07-19 SG SG11202100420UA patent/SG11202100420UA/en unknown
- 2019-07-19 AU AU2019312139A patent/AU2019312139B2/en active Active
- 2019-07-19 EA EA202190335A patent/EA202190335A1/ru unknown